Jefferies is out with some price target revisions and color after conducting a "global pharma...

Jefferies is out with some price target revisions and color after conducting a "global pharma review." Rundown: Top U.S. pick Abbott Laboratories (ABT +1.9%) reiterated at Buy, PT lowered to $44 from $46; top global pick Novartis (NVS +0.3%) has "positive growth inflection potential" in FY14; AbbVie (ABBV +0.6%), Roche (RHHBY.OB +2.5%), and Sanofi (SNY +0.5%) offer "attractive entry points" but ABBV's PT is lowered to $51 from $54; Johnson & Johnson's (JNJ +0.2%) PT lowered to $91 from $97; Merck (MRK -0.3%) has its price target raised to $56 from $54 and Pfizer (PFE +1.3%) has its target lowered slightly to $32. (Previous: Jefferies SOTP analysis)

From other sites
Comments (3)
  • Prescient Investment Analysis
    , contributor
    Comments (262) | Send Message
    The Bezinga page hyperlinked to "$54" shows MRK's price target being raised from $54 to $56.
    7 Jun 2013, 03:28 PM Reply Like
  • financeminister
    , contributor
    Comments (1212) | Send Message
    They didn't tell when to expect these price targets.... yeah, didn't think so. They just throw some numbers out there and wait for father christmas.
    7 Jun 2013, 04:22 PM Reply Like
  • Jay Adler Comment
    , contributor
    Comments (49) | Send Message
    I think Pfizer is going to hit the lottery drug one day, huge research company, business acumen. I am not just saying this because I am glad I own a nice position.
    7 Jun 2013, 09:59 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs